Abstract
Ixekizumab is a human immunoglobulin G4 monoclonal antibody targeting interleukin-17A. Clinical trials have reported that 82-84% of the patients using......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
